Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer

BACKGROUND: Circulating tumor DNA (ctDNA) has made a breakthrough as an early biomarker in operable early‐stage cancer patients. However, the function of ctDNA combined with cell‐free DNA (cfDNA) as a predictor in advanced non‐small cell lung cancer (NSCLC) remains unknown. Here, we explored its pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Jie, Wang, Yubo, Hu, Chen, Zhu, Mengxiao, Ii, Jianghua, Lin, Caiyu, Lu, Conghua, Dou, Yuanyao, Zhao, Chenlong, Zhang, Yimin, Wu, Di, Li, Li, Tang, Huan, He, Tingting, Pan, Chunxiao, Han, Rui, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663669/
https://www.ncbi.nlm.nih.gov/pubmed/36193794
http://dx.doi.org/10.1111/1759-7714.14668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663669/
https://www.ncbi.nlm.nih.gov/pubmed/36193794
http://dx.doi.org/10.1111/1759-7714.14668

Ejemplares similares